Veraxa Biotech's BiTAC — ADC Shows Tumor Regression in Preclinical Breast Cancer Study
Veraxa Biotech presented initial animal proof-of-concept results for its BiTAC-ADC cancer platform on October 13, 2026, at the World ADC Congress. A single 3 mg/kg dose produced strong tumor regression in a breast cancer xenograft model, with efficacy comparable to a conventional ADC. No body weight decline occurred in the BiTAC-ADC treatment group; delivering only one targeted component produced no significant effect. Laboratory studies showed both components must reach tumor cells to activate toxicity, with no active toxins released in the periphery. BiTAC-TCEs remain the development priority, while the ADC results support a potential second research and partnering focus. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissi
Veraxa Biotech presented initial animal proof-of-concept results for its BiTAC-ADC cancer platform on October 13, 2026, at the World ADC Congress. A single 3 mg/kg dose produced strong tumor regression in a breast cancer xenograft model, with efficacy comparable to a conventional ADC. No body weight decline occurred in the BiTAC-ADC treatment group; delivering only one targeted component produced no significant effect. Laboratory studies showed both components must reach tumor cells to activate toxicity, with no active toxins released in the periphery.
BiTAC-TCEs remain the development priority, while the ADC results support a potential second research and partnering focus. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S.
Securities and Exchange Commission (Ref. ID: 0001829126-26-011185), on October 15, 2026, and is solely responsible for the information contained therein. (C)